Profile data is unavailable for this security.
About the company
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
- Revenue in USD (TTM)45.32m
- Net income in USD-290.42m
- Incorporated--
- Employees142.00
- LocationImmatics NVPaul Ehrlich-Strasse 15TUEBINGEN 72076GermanyDEU
- Phone+49 70 715397700
- Websitehttps://immatics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | 0.00 | -99.83m | 858.65m | 50.00 | -- | 3.21 | -- | -- | -4.12 | -4.12 | 0.00 | 9.56 | 0.00 | -- | -- | 0.00 | -56.79 | -73.75 | -61.82 | -83.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -149.24 | -- | 216.18 | -- |
| Akero Therapeutics Inc | 0.00 | -95.14m | 867.71m | 28.00 | -- | 3.94 | -- | -- | -2.75 | -2.75 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -54.04 | -- | -58.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -81.02 | -- | -- | -- |
| Phibro Animal Health Corp | 833.35m | 54.39m | 876.90m | 1.73k | 16.12 | 3.68 | 10.16 | 1.05 | 1.34 | 1.34 | 20.57 | 5.89 | 1.03 | 2.72 | 6.10 | 483,101.40 | 6.69 | 7.77 | 8.34 | 9.72 | 32.56 | 32.33 | 6.53 | 6.78 | 1.72 | 8.91 | 0.6218 | 32.56 | 4.12 | 2.09 | 62.09 | -8.05 | -4.21 | 3.71 |
| Crinetics Pharmaceuticals Inc | 0.00 | -88.96m | 879.25m | 93.00 | -- | 4.26 | -- | -- | -2.61 | -2.61 | 0.00 | 5.35 | 0.00 | -- | -- | 0.00 | -40.99 | -- | -43.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -94.05 | -- | -46.39 | -- | -- | -- |
| Amphastar Pharmaceuticals Inc | 384.04m | 10.45m | 882.34m | 1.98k | 87.05 | 2.09 | 24.91 | 2.30 | 0.211 | 0.211 | 7.73 | 8.79 | 0.6068 | 2.16 | 6.52 | 193,957.10 | 1.83 | 2.19 | 2.42 | 2.75 | 43.14 | 39.46 | 3.02 | 3.72 | 1.71 | -- | 0.0762 | 0.00 | 8.53 | 6.82 | -97.13 | -- | 18.62 | -- |
| Praxis Precision Medicines Inc | 0.00 | -110.59m | 892.46m | 67.00 | -- | 2.67 | -- | -- | -2.79 | -2.79 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -56.20 | -- | -60.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.86 | -- | -- | -- |
| Beyondspring Inc | 856.00k | -68.43m | 896.13m | 91.00 | -- | 16.21 | -- | 1,046.88 | -1.93 | -1.93 | 0.0241 | 1.41 | 0.0132 | -- | -- | 9,406.59 | -109.70 | -165.62 | -142.64 | -226.45 | -- | -- | -8,282.36 | -150,311.70 | -- | -- | 0.0364 | -- | -- | -- | -60.10 | -- | 5.39 | -- |
| Sutro Biopharma Inc | 68.81m | -78.92m | 908.18m | 204.00 | -- | 2.95 | -- | 13.20 | -1.82 | -1.82 | 1.62 | 6.66 | 0.2159 | -- | 9.65 | 360,261.80 | -24.76 | -- | -27.41 | -- | -- | -- | -114.69 | -- | -- | -4.39 | 0.0747 | -- | -0.0328 | -- | 42.37 | -- | -- | -- |
| Immatics NV | 45.32m | -290.42m | 920.98m | 142.00 | -- | 8.38 | -- | 20.32 | -4.58 | -4.58 | 0.7501 | 1.75 | 0.2071 | -- | -- | 319,183.70 | -133.00 | -- | -164.76 | -- | -- | -- | -642.20 | -- | -- | -15.89 | 0.0635 | -- | 69.40 | -- | -625.54 | -- | -- | -- |
| Stoke Therapeutics Inc | 0.00 | -67.01m | 927.55m | 79.00 | -- | 3.63 | -- | -- | -1.88 | -1.88 | 0.00 | 6.95 | 0.00 | -- | -- | 0.00 | -28.23 | -- | -29.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.62 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | -100.00bn | -100.00bn | 939.19m | 104.00 | -- | 3.89 | -- | -- | -- | -- | -- | 8.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 94.85 | -- | -14.98 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -620.31k | 950.39m | 0.00 | -- | -- | -- | -- | -0.0029 | -0.0029 | 0.00 | -0.0012 | 0.00 | -- | -- | -- | -4,067.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Singular Genomics Systems Inc | 0.00 | -77.25m | 958.14m | 169.00 | -- | 2.61 | -- | -- | -1.10 | -1.10 | 0.00 | 5.13 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.12 | 0.0254 | -- | -- | -- | -126.75 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 1.52m | -91.49m | 962.83m | 43.00 | -- | 4.49 | -- | 635.11 | -1.89 | -1.89 | 0.0314 | 4.41 | 0.0067 | -- | 4.63 | 35,255.81 | -40.16 | -52.37 | -43.68 | -59.73 | -- | -- | -6,035.16 | -3,914.71 | -- | -44.25 | 0.0866 | -- | 0.00 | 19.33 | -37.50 | -- | -- | -- |
| OraSure Technologies, Inc. | 227.06m | 5.31m | 963.48m | 570.00 | 182.94 | 2.38 | 63.22 | 4.24 | 0.0731 | 0.0731 | 3.14 | 5.62 | 0.5126 | 2.36 | 7.42 | 398,342.10 | 1.20 | 3.69 | 1.31 | 4.10 | 60.55 | 61.87 | 2.34 | 6.86 | 5.09 | 19.47 | 0.0064 | 0.00 | 11.07 | 7.48 | -189.59 | -- | 50.52 | -- |
| Glucose Health Inc | 88.13k | -85.06k | 984.08m | 2.00 | -- | -- | -- | 11,166.24 | -0.0282 | -0.0282 | 0.0243 | -0.0944 | 2.51 | -- | 8.45 | -- | -241.96 | -751.92 | -- | -- | 65.39 | 5.48 | -96.52 | -999.86 | -- | -0.293 | -- | -- | 7,235.60 | -- | -54.27 | -- | -- | -- |
Data as of Sep 20 2021. Currency figures normalised to Immatics NV's reporting currency: US Dollar USD
28.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Jun 2021 | 4.28m | 6.81% |
| Nantahala Capital Management LLCas of 30 Jun 2021 | 2.54m | 4.05% |
| Perceptive Advisors LLCas of 30 Jun 2021 | 2.50m | 3.97% |
| Alyeska Investment Group LPas of 30 Jun 2021 | 2.15m | 3.42% |
| Redmile Group LLCas of 30 Jun 2021 | 1.94m | 3.09% |
| Federated Global Investment Management Corp.as of 30 Jun 2021 | 1.76m | 2.79% |
| 683 Capital Management LLCas of 30 Jun 2021 | 1.18m | 1.88% |
| University of Texas Investment Management Co.as of 30 Jun 2021 | 697.43k | 1.11% |
| Woodline Partners LPas of 30 Jun 2021 | 548.93k | 0.87% |
| RTW Investments LPas of 30 Jun 2021 | 350.00k | 0.56% |
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
